• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

UBS upgrades Azelis to ‘buy,’ citing recovery and attractive valuation

by January 17, 2025
written by January 17, 2025

Investing.com — UBS Global Research has upgraded Azelis Group (EBR:AZE) to a “buy” rating from its previous “neutral” stance. 

Shares of the Belgium-based company were up 3.8% at 08:12 ET (13:12 GMT).

UBS believes profit pressures have peaked, making the company’s current valuation attractive.

Azelis saw profit normalization in 2024, following a period of exceptional growth from 2020 to 2022

While the chemical distribution sector faced challenges in the past year, UBS projects 2025 to be a more typical year, characterized by modest volume recovery and easing pricing pressures. 

The analysts foresee conversion margins stabilizing at about 45%, which remains higher than pre-2020 levels and above the low 40% range implied by current market valuations.

UBS has adjusted its price target for Azelis upward, from €19 to €22, reflecting a 1% increase in expected earnings per share and the inclusion of potential bolt-on mergers and acquisitions into its discounted cash flow valuation model. 

The brokerage notes that Azelis has historically been active in mergers and acquisitions, a key growth strategy in the fragmented chemical distribution market. 

With a conservative assumption of €150 million in annual mergers and acquisitions spending, the valuation captures the company’s ongoing potential to expand its market share.

Despite cautious commentary from Azelis management regarding customer ordering patterns, UBS forecasts a 4.5% year-over-year volume growth for 2025. 

Pricing pressures may persist into the first half of the year, but the overall risk of a margin reset appears limited. 

The analysts also flag the resilience of the chemical distribution industry, which benefits from structural growth and defensive demand patterns.

Trading at around 12 times its estimated 2025 EV/EBITA, Azelis represents a 25% discount compared to peer IMCD (AS:IMCD), despite comparable growth outlooks. 

UBS flags an attractive entry point for investors due to Azelis’s valuation gap. Analysts said that the company’s long-term growth potential as a top-three player in a diverse and expanding market.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Rivian, Apple, Salesforce rise premarket;JB Hunt Transport falls
next post
Apple pauses AI news summaries due to accuracy concerns

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • ‘Shark Tank’ alum Bombas taps former Under Armour exec as CEO as it looks beyond digital roots

      May 16, 2025
    • Netflix says its ad tier now has 94 million monthly active users

      May 15, 2025
    • Dick’s Sporting Goods to buy struggling Foot Locker for $2.4 billion

      May 15, 2025
    • YouTube will stream NFL Week 1 game in Brazil for free

      May 15, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (464)
    • Stock (6,426)

    Latest News

    • ‘Shark Tank’ alum Bombas taps former Under Armour exec as CEO as it looks beyond digital roots
    • Netflix says its ad tier now has 94 million monthly active users

    Popular News

    • Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
    • Investors lean toward ‘Trump trade’ but say race too close to call

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy